Sinclair Pharma Plc (SPH) - Financial and Strategic SWOT Analysis Review

June 2018 | 49 pages | ID: S6F6573E627EN
GlobalData

Abstracts

Sinclair Pharma Plc (SPH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Key manufacturing facilities – A list of key manufacturing facilities of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Sinclair Pharma plc (Sinclair), formerly Sinclair IS Pharma plc, is an aesthetics company, which strives to provide dermatological solutions. The company develops, manufactures and distributes dermatological products for facial aesthetics, particularly for facial rejuvenation, through collagen stimulation. It offers complementary aesthetics technologies; and longer duration, natural looking and minimally-invasive treatments. It also offers dermal fillers for folds and lines. Some of Sinclair’s major products include Silhouette Soft; Ellanse; Perfectha and Sculptra. It has direct sales and marketing presence in five major European countries and Brazil. It also has multi-product and multi-country distribution partnerships with several companies. Sinclair is headquartered in London, the UK.

Sinclair Pharma Plc Key Recent Developments

Apr 30,2018: Sinclair Pharma: Preliminary results for 12 months ended 31 December 2017
Apr 30,2018: Sinclair secures €23 million debt facility
Jan 16,2018: Sinclair Pharma: Ellanse Approved for Brazil
Sep 19,2017: Sinclair Pharma: Interim Results
Jul 11,2017: Sinclair Pharma: Trading Update for the 6 months to 30 June 2017

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Sinclair Pharma Plc - Key Facts
Sinclair Pharma Plc - Key Employees
Sinclair Pharma Plc - Key Employee Biographies
Sinclair Pharma Plc - Major Products and Services
Sinclair Pharma Plc - History
Sinclair Pharma Plc - Company Statement
Sinclair Pharma Plc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Sinclair Pharma Plc - Business Description
R&D Overview
Sinclair Pharma Plc - SWOT Analysis
SWOT Analysis - Overview
Sinclair Pharma Plc - Strengths
Sinclair Pharma Plc - Weaknesses
Sinclair Pharma Plc - Opportunities
Sinclair Pharma Plc - Threats
Sinclair Pharma Plc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Sinclair Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Sinclair Pharma Plc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Sinclair Pharma Plc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Apr 30, 2018: Sinclair Pharma: Preliminary results for 12 months ended 31 December 2017
Apr 30, 2018: Sinclair secures €23 million debt facility
Jan 16, 2018: Sinclair Pharma: Ellanse Approved for Brazil
Sep 19, 2017: Sinclair Pharma: Interim Results
Jul 11, 2017: Sinclair Pharma: Trading Update for the 6 months to 30 June 2017
Mar 30, 2017: Sinclair Pharma: Additional listing
Mar 21, 2017: Sinclair Pharma Announces Preliminary results for the 12 and 18 months ended 31 December 2016
Jan 17, 2017: Sinclair Pharma Announces Pre-Close Trading Update

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Sinclair Pharma Plc, Key Facts
Sinclair Pharma Plc, Key Employees
Sinclair Pharma Plc, Key Employee Biographies
Sinclair Pharma Plc, Major Products and Services
Sinclair Pharma Plc, History
Sinclair Pharma Plc, Other Locations
Sinclair Pharma Plc, Subsidiaries
Sinclair Pharma Plc, Key Competitors
Sinclair Pharma Plc, Ratios based on current share price
Sinclair Pharma Plc, Annual Ratios
Sinclair Pharma Plc, Annual Ratios (Cont.1)
Sinclair Pharma Plc, Interim Ratios
Sinclair Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Sinclair Pharma Plc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Sinclair Pharma Plc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Sinclair Pharma Plc, Performance Chart (2013 - 2017)
Sinclair Pharma Plc, Ratio Charts
Sinclair Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Sinclair Pharma Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018

COMPANIES MENTIONED

Valeant Pharmaceuticals International Inc
Merz Pharmaceuticals GmbH
Maruho Co Ltd
Galderma SA